AI Engines For more Details: Perplexity Kagi Labs You
Osteoarthritis (OA): Diacerein is indicated for the symptomatic treatment of osteoarthritis, particularly in the knees and hips. It works by inhibiting the activity of interleukin-1 beta (IL-1Ξ²), a pro-inflammatory cytokine that plays a key role in the pathophysiology of osteoarthritis. By reducing the production of IL-1Ξ², diacerein helps suppress inflammation and slow down the progression of cartilage degradation in affected joints.
Anti-Inflammatory Action: Diacerein exerts anti-inflammatory effects by blocking the action of IL-1Ξ², which is involved in promoting inflammation, cartilage destruction, and pain in osteoarthritic joints. By inhibiting IL-1Ξ², diacerein helps reduce joint swelling, stiffness, and pain, thereby improving overall joint function and mobility in individuals with osteoarthritis.
Chondroprotective Effects: In addition to its anti-inflammatory properties, diacerein has been shown to have chondroprotective effects, meaning it helps protect and preserve cartilage integrity in osteoarthritic joints. Diacerein may stimulate the synthesis of proteoglycans and other extracellular matrix components in cartilage, promoting cartilage repair and regeneration.
Symptom Relief: Diacerein provides symptomatic relief of osteoarthritis symptoms such as joint pain, swelling, stiffness, and functional impairment. It helps improve mobility and quality of life for individuals affected by osteoarthritis, allowing them to better tolerate physical activity and perform daily tasks with less discomfort.
Oral Administration: Diacerein is typically administered orally in capsule or tablet form, usually once daily, as directed by a healthcare provider. The dosage may vary depending on the individual's age, weight, severity of osteoarthritis, and response to treatment. It's important to follow the prescribed dosage and administration instructions carefully to achieve optimal therapeutic outcomes.
Onset of Action: Diacerein may take several weeks to months to achieve its maximum therapeutic effect in osteoarthritis. While some individuals may experience symptom relief within a few weeks of starting diacerein therapy, others may require longer treatment durations to fully benefit from its chondroprotective and anti-inflammatory effects.
Side Effects: Common side effects of diacerein may include gastrointestinal upset (such as abdominal pain, diarrhea, nausea, and flatulence), which may occur in some individuals due to its irritant effect on the gastrointestinal tract. These side effects are usually mild and transient but may improve with continued use or dose adjustment. In rare cases, severe gastrointestinal adverse effects such as colitis or liver toxicity may occur and require medical attention.
Contraindications: Diacerein is contraindicated in individuals with known hypersensitivity or allergy to the medication or its components. It should be used with caution in individuals with pre-existing gastrointestinal disorders, liver dysfunction, or renal impairment, as these conditions may increase the risk of adverse effects.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 4.3 | 0.9 | 3.78 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 2.2 | 0.55 |
| Allergies | 9.3 | 4.7 | 0.98 |
| Allergy to milk products | 2.5 | 1.6 | 0.56 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 8.8 | 8.2 | 0.07 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.3 | 1.4 | 2.07 |
| Ankylosing spondylitis | 5.2 | 1.8 | 1.89 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 2 | 0.3 | 5.67 |
| Asthma | 5.9 | 2.7 | 1.19 |
| Atherosclerosis | 2.6 | 3 | -0.15 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 12.4 | 10.6 | 0.17 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.9 | 2.9 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.7 | 0.3 | 4.67 |
| Cancer (General) | 0.9 | 1.8 | -1 |
| Carcinoma | 5.2 | 2.6 | 1 |
| Celiac Disease | 3.5 | 3.7 | -0.06 |
| Cerebral Palsy | 1.8 | 1.3 | 0.38 |
| Chronic Fatigue Syndrome | 6.5 | 7.6 | -0.17 |
| Chronic Kidney Disease | 5.2 | 3.3 | 0.58 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.9 | 2 | 0.45 |
| Chronic Urticaria (Hives) | 1.9 | 1.8 | 0.06 |
| Coagulation / Micro clot triggering bacteria | 1.8 | 1.3 | 0.38 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 11.2 | 3.4 | 2.29 |
| Constipation | 2.1 | 1.3 | 0.62 |
| Coronary artery disease | 2.9 | 3 | -0.03 |
| COVID-19 | 10.9 | 14.4 | -0.32 |
| Crohn's Disease | 10.2 | 6.9 | 0.48 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.1 | 1.3 | -0.18 |
| d-lactic acidosis (one form of brain fog) | 0.5 | 0.5 | |
| deep vein thrombosis | 4 | 1.4 | 1.86 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 12.3 | 10.6 | 0.16 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 2.6 | -0.13 |
| Endometriosis | 3.4 | 2.5 | 0.36 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4.3 | 2.8 | 0.54 |
| erectile dysfunction | 2.6 | 0.3 | 7.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 6.3 | 4.9 | 0.29 |
| gallstone disease (gsd) | 4.2 | 1.6 | 1.63 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 3.7 | 2.4 | 0.54 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 3.1 | 1.5 | 1.07 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.5 | -1.78 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4.4 | 2.2 | 1 |
| Heart Failure | 5.3 | 2.3 | 1.3 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 1 | 0.6 | 0.67 |
| hyperglycemia | 2.9 | 2.2 | 0.32 |
| Hyperlipidemia (High Blood Fats) | 1.3 | 0.3 | 3.33 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.7 | 5.7 | 0 |
| Hypothyroidism | 0.4 | 1 | -1.5 |
| Hypoxia | 3.9 | 0.9 | 3.33 |
| IgA nephropathy (IgAN) | 1.9 | 5.5 | -1.89 |
| Inflammatory Bowel Disease | 11.5 | 10.8 | 0.06 |
| Insomnia | 2.8 | 3.5 | -0.25 |
| Intelligence | 1.9 | 0.6 | 2.17 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 9.9 | 6.3 | 0.57 |
| ischemic stroke | 3.1 | 1.7 | 0.82 |
| Liver Cirrhosis | 9 | 5.8 | 0.55 |
| Long COVID | 8.7 | 8.1 | 0.07 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.6 | -0.07 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1 | 1 | 0 |
| Metabolic Syndrome | 9.3 | 8.4 | 0.11 |
| Mood Disorders | 12.4 | 8.5 | 0.46 |
| multiple chemical sensitivity [MCS] | 1.6 | 0.1 | 15 |
| Multiple Sclerosis | 8.4 | 7 | 0.2 |
| Multiple system atrophy (MSA) | 2.2 | 0.7 | 2.14 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.2 | 2.8 | -1.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.1 | 1.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.4 | 4.8 | 0.33 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 13.3 | 9.5 | 0.4 |
| obsessive-compulsive disorder | 6.9 | 4.8 | 0.44 |
| Osteoarthritis | 3.3 | 1.6 | 1.06 |
| Osteoporosis | 3.1 | 2.2 | 0.41 |
| pancreatic cancer | 2.3 | 0.6 | 2.83 |
| Parkinson's Disease | 10.4 | 8.3 | 0.25 |
| Polycystic ovary syndrome | 7.9 | 3.7 | 1.14 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 4.3 | 4 | 0.07 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9 | 4.7 | 0.91 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 7.3 | 3.5 | 1.09 |
| scoliosis | 0.8 | 1.2 | -0.5 |
| Sjögren syndrome | 3.2 | 2.6 | 0.23 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.4 | 0.3 | 3.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.1 | 0.1 | 20 |
| Stress / posttraumatic stress disorder | 3.6 | 3.3 | 0.09 |
| Systemic Lupus Erythematosus | 4.9 | 2.4 | 1.04 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.3 | 0.3 | 3.33 |
| Type 1 Diabetes | 6.3 | 3.3 | 0.91 |
| Type 2 Diabetes | 10.3 | 8.9 | 0.16 |
| Ulcerative colitis | 7.5 | 8.8 | -0.17 |
| Unhealthy Ageing | 6.8 | 2.9 | 1.34 |
| Vitiligo | 2.5 | 2 | 0.25 |
